HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Knowledge on whether low expressions of HER2 have prognostic impact in early-stage breast cancer (BC) and on its response to current chemotherapy protocols can contribute to medical practice and development of new drugs for this subset of patients, changing treatment paradigms. This study aims to evaluate the impact of HER2-low status on response to neoadjuvant chemotherapy (NACT) and survival outcomes in early-stage HER2-negative BC. Records from all BC patients treated with NACT from January 2007 to December 2018 in a single cancer center were retrospectively reviewed. HER2-negative (immunohistochemistry [IHC] 0, + 1, or + 2 non-amplified by in situ hybridization [ISH]) patients were included. HER2-low was defined by IHC + 1 or + 2 ISH non-amplified and HER2-0 by IHC 0. The coprimary objectives were to compare pathological complete response (pCR) and relapse-free survival (RFS) between luminal/HER2-low versus luminal/HER2-0 populations and between triple negative (TNBC)/HER2-low versus TNBC/HER2-0. In total, 855 HER2-negative patients were identified. The median follow-up was 59 months. 542 patients had luminal subtype (63.4%) and 313 had TNBC (36.6%). 285 (33.3%) were HER2-low. Among luminal patients, 145 had HER2 IHC + 1 (26.8%) and 91 had IHC + 2/ISH non-amplified (16.8%). In TNBC, 36 had HER2 IHC + 1 (11.5%) and 13 had IHC + 2/ISH non-amplified (4.2%). Most patients had locally advanced tumors, regardless of subtype or HER2-low status. For luminal disease, pCR was achieved in 13% of HER2-low tumors versus 9.5% of HER2-0 (p = 0.27). Similarly, there was no difference in pCR rates among TNBC: 51% versus 47% in HER2-low versus HER2-0, respectively (p = 0.64). HER2-low was also not prognostic for RFS, with 5-year RFS rates of 72.1% versus 71.7% (p = 0.47) for luminal HER2-low/HER2-0, respectively, and 75.6% versus 70.8% (p = 0.23) for TNBC HER2-low/HER2-0. Our data does not support HER2-low as a biologically distinct BC subtype, with no prognostic value on survival outcomes and no predictive effect for pCR after conventional NACT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Cited by
Tarantino, P., Viale, G., Press, M. F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H. J., Carey, L. A., Cortes, J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.008 · Cited by 312
Metadata
- Authors
- de Moura Leite, L., Cesca, M. G., Tavares, M. C., Santana, D. M., Saldanha, E. F., Guimarães, P. T., Sá, D. D. S., Simões, M. F. E., Viana, R. L., Rocha, F. G., Loose, S. K., Silva, S. F., Pirolli, R., Fogassa, C. A. Z., Mattos, B. R. S., Campos, F. A. B., Sanches, S. M., de Lima, V. C. C., & Pondé, N. F.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2021-08-18
- Volume
- 190
- Issue
- 1
- Pages
- 155-163
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W3160468108
- Cited by
- 168
- References
- 1
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. https://app.cochat.ai/papers/10.1007/s10549-021-06365-7
- The paper
- de Moura Leite, L., Cesca, M. G., Tavares, M. C., Santana, D. M., Saldanha, E. F., Guimarães, P. T., Sá, D. D. S., Simões, M. F. E., Viana, R. L., Rocha, F. G., Loose, S. K., Silva, S. F., Pirolli, R., Fogassa, C. A. Z., Mattos, B. R. S., Campos, F. A. B., Sanches, S. M., de Lima, V. C. C., & Pondé, N. F. (2021). HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-021-06365-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.